A randomised trial of evaluating a systematic intensive therapy using Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring (FGM) in clinical diabetes care

This study is a randomised, non-blinded, multi-centre, clinical study for persons with type 1 diabetes and HbA1c ≥ 58mmol/mol and treated with CGM or FGM. The main aim is to analyse if intensive systematic treatment via internet and telephone during 4 months improved HbA1c for persons with type 1 diabetes which are already treated with CGM or FGM, and if the effect continuous for 1-2 years after the intervention stops.

News from 2021:
This project had ongoing recruitment in 2021/2022.

Primary Investigator: Kari Anne Sveen

Co-investigators/participants: 
Marcus Lind, MD, PhD, Diabetes Section Uddevalla Hospital,Sweden- PI Sweden
Arndís F. Olafsdottir RN, PgD, Uddevalla, Sweden
Kåre. I. Birkeland, Department of Transplantation/Professor of Internal Medicine, Oslo University Hospital/ University of Oslo, Norway